



Correction for Evans et al., “Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against *Acinetobacter* spp. in PRIMERS III”

Scott R. Evans,^a Andrea M. Hujer,^{b,c} Hongyu Jiang,^a Carol B. Hill,^d
Kristine M. Hujer,^{b,c} Jose R. Mediavilla,^e Claudia Manca,^e Thuy Tien T. Tran,^a
T. Nicholas Domitrovic,^{b,c} Paul G. Higgins,^{f,g} Harald Seifert,^{f,g} Barry N. Kreiswirth,^e
Robin Patel,^h Michael R. Jacobs,ⁱ Liang Chen,^e Rangarajan Sampath,^j Thomas Hall,^j
Christine Marzan,^j Vance G. Fowler, Jr.,^{d,k} Henry F. Chambers,^l
Robert A. Bonomo,^{b,c,m} for the Antibacterial Resistance Leadership Group (ARLG)

Center for Biostatistics in AIDS Research and the Department of Biostatistics, Harvard University, Boston, Massachusetts, USA^a; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA^b; Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA^c; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA^d; Public Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark, New Jersey, USA^e; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany^f; German Center for Infection Research (DZIF), Partner Site Bonn, Cologne, Germany^g; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA^h; Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USAⁱ; IBIS Biosciences Inc., an Abbott Company, Carlsbad, California, USA^j; Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA^k; University of California, San Francisco General Hospital, San Francisco, California, USA^l; Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA^m

Volume 55, no. 1, p. 134–144, 2017, <https://doi.org/10.1128/JCM.01524-16>. Table S1 in the supplemental material: Isolates PR-369 and PR-469 were mislabeled, and a column containing an alternate list of isolate names (ARLG IDs) was inadvertently omitted. Revised supplemental material is posted at <http://jcm.asm.org/content/55/1/134/suppl/DCSupplemental>.

Citation Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TTT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG, Jr., Chambers HF, Bonomo RA, for the Antibacterial Resistance Leadership Group (ARLG). 2017. Correction for Evans et al., “Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics to identify susceptibility and resistance to carbapenems against *Acinetobacter* spp. in PRIMERS III.” *J Clin Microbiol* 55:1970. <https://doi.org/10.1128/JCM.00525-17>.

Copyright © 2017 American Society for Microbiology. All Rights Reserved.